GlassScriptPhysician profile
Laura N Hollar
NPI 1376963470
$2,615.84
in general payments reported to CMS, 2019-2025
14 companies · $208 in 2025
The $208 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $158 · 2021: $203 · 2022: $341 · 2023: $824 · 2024: $674 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,663 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,663.07 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $538.87 | 2021-2024 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Abbott Laboratories | $526.13 | 2020-2023 | Freestyle Libre 3 |
| Amgen INC. | $306.80 | 2019-2024 | Evenity, Prolia, Tepezza |
| Insulet Corporation | $296.06 | 2022-2025 | Omnipod |
| Novo Nordisk INC | $164.10 | 2023-2024 | Rybelsus, Ozempic, Tresiba |
| Tandem Diabetes Care, INC. | $145.67 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals LP | $120.30 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.92 | 2020 | |
| Renalytix Ai, INC. | $98.69 | 2022 | |
| Astellas Pharma US INC | $96.75 | 2024-2025 | Veozah |
| Lilly USA, LLC | $85.34 | 2023 | |
| Cequr Corporation | $55.28 | 2023-2025 | Cequr Simplicity |
| Mannkind Corporation | $42.50 | 2025 | |
| Amneal Pharmaceuticals LLC | $21.43 | 2025 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Hollar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.